Rapid Micro Biosystems, Inc. (RPID) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.44
↑+147% vs avg
5yr avg: 1.40
30Y Low0.3·High3.9
ROE
↓
-86.8%
↑-64% vs avg
5yr avg: -52.8%
30Y Low-308%·High-32%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RPID Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Rapid Micro Biosystems, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $114M | $130M | $39M | $32M | $48M | $441M | — | — |
| Enterprise Value | $118M | $133M | $28M | $15M | $29M | $263M | — | — |
| P/E Ratio → | -2.44 | — | — | — | — | — | — | — |
| P/S Ratio | 3.39 | 3.86 | 1.40 | 1.41 | 2.80 | 18.99 | — | — |
| P/B Ratio | 3.44 | 3.90 | 0.52 | 0.27 | 0.29 | 2.00 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RPID EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.97 | 1.02 | 0.66 | 1.69 | 11.31 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
RPID Profitability
Margins and return-on-capital ratios measuring operating efficiency
Rapid Micro Biosystems, Inc. earns an operating margin of -141.1%. Operating margins have expanded from -251.2% to -141.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -86.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 22.7% | 22.7% | -0.4% | -24.4% | -49.8% | -33.3% | -50.2% | -1.4% |
| Operating Margin | -141.1% | -141.1% | -178.0% | -251.2% | -369.0% | -203.3% | -190.0% | -112.9% |
| Net Profit Margin | -140.3% | -140.3% | -167.2% | -233.0% | -354.9% | -316.5% | -230.6% | -128.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -86.8% | -86.8% | -48.5% | -37.2% | -31.6% | -59.8% | -307.8% | — |
| ROA | -54.5% | -54.5% | -38.8% | -31.4% | -28.2% | -47.3% | -72.9% | -66.8% |
| ROIC | -69.9% | -69.9% | -45.2% | -34.5% | -50.5% | -114.0% | -189.5% | -302.4% |
| ROCE | -69.2% | -69.2% | -48.7% | -38.2% | -32.0% | -34.0% | -80.8% | -88.1% |
RPID Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $4M ($24M total debt minus $20M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.72 | 0.72 | 0.08 | 0.06 | 0.05 | — | 1.00 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.12 | -0.14 | -0.14 | -0.12 | -0.81 | -0.21 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -43.48 | -43.48 | — | — | — | -17.82 | -8.86 | -7.85 |
RPID Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Rapid Micro Biosystems, Inc.'s current ratio of 3.31x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.36x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 6.34x to 3.31x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.31 | 3.31 | 4.61 | 6.34 | 7.27 | 12.01 | 4.00 | 2.24 |
| Quick Ratio | 2.36 | 2.36 | 3.46 | 5.29 | 6.16 | 11.14 | 3.42 | 1.70 |
| Cash Ratio | 2.07 | 2.07 | 2.89 | 4.85 | 5.70 | 10.65 | 2.90 | 1.18 |
| Asset Turnover | — | 0.45 | 0.29 | 0.16 | 0.09 | 0.10 | 0.23 | 0.52 |
| Inventory Turnover | 1.48 | 1.48 | 1.39 | 1.40 | 1.21 | 1.98 | 2.69 | 2.91 |
| Days Sales Outstanding | — | 34.06 | 97.92 | 90.49 | 116.77 | 88.48 | 131.32 | 108.74 |
RPID Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Rapid Micro Biosystems, Inc. returns 0.1% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $45M | $44M | $43M | $42M | $41M | $39M | $40M |
Peer Comparison
Compare RPID with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RPIDYou | $114M | -2.4 | — | — | 22.7% | -141.1% | -86.8% | -69.9% | — |
 IDXX | $45B | 43.7 | 31.6 | 43.1 | 61.8% | 31.6% | 66.2% | 42.5% | 0.7 |
 NEOG | $2B | -1.8 | 20.7 | — | 47.1% | 1.1% | -41.9% | 0.2% | 6.8 |
 BRKR | $7B | -291.5 | 18.4 | 153.7 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 |
 AZTA | $855M | -15.2 | 13.8 | 22.3 | 45.5% | -1.9% | -3.2% | -0.5% | 2.2 |
 BIO | $7B | 9.2 | 16.7 | 18.5 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
 MESO | $2B | -17.6 | — | — | 70.2% | -363.1% | -19.0% | -8.5% | — |
 QGEN | $7B | 16.4 | 10.8 | 15.2 | 61.8% | 24.9% | 11.6% | 8.6% | 2.3 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $124B | 34.9 | 18.2 | 23.6 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See RPID's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RPID Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RPID vs IDXX
Side-by-side business, growth, and profitability comparison vs IDEXX Laboratories, Inc..
Start ComparisonRPID — Frequently Asked Questions
Quick answers to the most common questions about buying RPID stock.
What is Rapid Micro Biosystems, Inc.'s P/E ratio?
Rapid Micro Biosystems, Inc.'s current P/E ratio is -2.4x. This places it at the 50th percentile of its historical range.
What is Rapid Micro Biosystems, Inc.'s ROE?
Rapid Micro Biosystems, Inc.'s return on equity (ROE) is -86.8%. The historical average is -95.3%.
Is RPID stock overvalued?
Based on historical data, Rapid Micro Biosystems, Inc. is trading at a P/E of -2.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Rapid Micro Biosystems, Inc.'s profit margins?
Rapid Micro Biosystems, Inc. has 22.7% gross margin and -141.1% operating margin.